A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

Key Inclusion Criteria: * Confirmed genetic diagnosis of primary photoreceptor (PR) disease * Best corrected visual acuity (BCVA) in the study eye at Screening for Phase 1: Logmarithm of the minimum angle of resolution (LogMAR) 3.9 to LogMAR 1.0. BCVA at Screening for Phase 2: ETDRS letter score 20 and 60. * Retinal structure examination in the study eye demonstrating regions suitable for cell administration. Key Exclusion Criteria: * History of/currently active clinically relevant, ocular inflammation or infection * Glaucoma or other significant optic neuropathy * Diabetic macular edema or diabetic retinopathy * Clinically significant cystoid macular edema * Spherical equivalent refractive error of greater than 8.00 diopters myopia * Ocular surgery ≤3 months before Screening * Monocular vision (ie, no light perception in the fellow eye) * Presence of clinically significant anti-OpCT-001 Human Leukocyte Antigen (HLA) antibodies at Screening * Currently active malignancy, or history of malignancy within 5 years before OpCT-001 administration. Exception: Basal cell carcinoma that has been definitively treated. * Any current and active infection (bacterial/viral/fungal) that could put the participant at risk from immunosuppression * History of any cell therapy, gene therapy, or retinal implant at any time * Previously received a bone marrow or solid organ transplant